US2009312258A1PendingUtilityA1

Uses of human zven proteins and polynucleotides

69
Individually held — no corporate assignee on recordPriority: Oct 7, 2002Filed: Jun 12, 2009Published: Dec 17, 2009
Est. expiryOct 7, 2022(expired)· nominal 20-yr term from priority
Inventors:Katherine E. LewisPaul O. SheppardRobert R. West
A61P 37/00A61P 29/00G01N 2800/06A61P 1/04A61P 1/00G01N 33/6893C07K 14/47G01N 2800/065A61K 38/1709C07K 14/4702
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

Claims

exact text as granted — not AI-modified
1 . A method of stimulating gastrointestinal contractility in a mammal in need thereof, comprising:
 administering to the mammal a synergistically effective amount of a first polypeptide comprising the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5, and a second_polypeptide comprising the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2 and measuring gastrointestinal contractility in said mammal.   
     
     
         2 . The method of  claim 1 , wherein the first polypeptide is administered to the mammal, followed by administration of the second polypeptide to the mammal. 
     
     
         3 . The method of  claim 1 , wherein the first polypeptide consists essentially of the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5. 
     
     
         4 . The method of  claim 1 , wherein the first polypeptide consists of the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5. 
     
     
         5 . The method of  claim 1 , wherein the second polypeptide consists essentially of the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2. 
     
     
         6 . The method of  claim 1 , wherein the second polypeptide consists of the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2. 
     
     
         7 . The method of  claim 1 , wherein the first polypeptide and the second polypeptide are administered with a pump or an implant. 
     
     
         8 . The method of  claim 1 , wherein the first and second polypeptides are administered orally. 
     
     
         9 . A method of stimulating intestinal transit in a mammal in need thereof, comprising:
 administering to the mammal a synergistically effective amount of a first polypeptide comprising the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5, and a second polypeptide comprising the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2 and measuring intestinal transit in said mammal.   
     
     
         10 . The method of  claim 9 , wherein the first polypeptide is administered to the mammal, followed by administration of the second polypeptide to the mammal. 
     
     
         11 . The method of  claim 9 , wherein the first polypeptide consists essentially of the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5. 
     
     
         12 . The method of  claim 9 , wherein the first polypeptide consists of the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5. 
     
     
         13 . The method of  claim 9 , wherein the second polypeptide consists essentially of the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2. 
     
     
         14 . The method of  claim 9 , wherein the second polypeptide consists of the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2. 
     
     
         15 . The method of  claim 9 , wherein the first polypeptide and the second polypeptide are administered with a pump or an implant. 
     
     
         16 . The method of  claim 9 , wherein the first and second polypeptides are administered orally. 
     
     
         17 . A method of stimulating gastric emptying in a mammal in need thereof, comprising:
 administering to the mammal a synergistically effective amount of a first polypeptide comprising the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5, and administering a second polypeptide comprising the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2 and measuring gastric emptying in said mammal.   
     
     
         18 . The method of  claim 17 , wherein the first polypeptide is administered to the mammal, followed by administration of the second polypeptide to the mammal. 
     
     
         19 . The method of  claim 17 , wherein the first polypeptide consists essentially of the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5. 
     
     
         20 . The method of  claim 17 , wherein the first polypeptide consists of the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO: 5. 
     
     
         21 . The method of  claim 17 , wherein the second polypeptide consists essentially of the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2. 
     
     
         22 . The method of  claim 17 , wherein the second polypeptide consists of the amino acid sequence of amino acid residues 28 to 108 of SEQ ID NO: 2. 
     
     
         23 . The method of  claim 17 , wherein the first polypeptide and the second polypeptide are administered with a pump or an implant. 
     
     
         24 . The method of  claim 17 , wherein the first and second polypeptides are administered orally.

Join the waitlist — get patent alerts

Track US2009312258A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.